No profile data available.
Immuron Limited (IMRN) is a healthcare company in the nutritional and natural health products industry, based in Carlton, Australia, with about 7 full-time employees.
Australia was its largest region in fiscal year 2025, with 72% of revenue. Its market capitalization was $8.72 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended June 30, 2024; market data as of October 9, 2026.
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.
Australia: 72% of revenue by region in fiscal year 2025, followed by United States (23%).
$8.72 million as of October 9, 2026.
Listed companies of a similar size in the same industry (nutritional and natural health products) include Universe Pharmaceuticals INC (UPC), Healthy Extracts Inc. (HYEX), Mannatech, Incorporated (MTEX), Vynleads, Inc. (VYND).